At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Multicenter, Double-blind, Randomized, Parallel Group, 4-week Inpatient Study To Evaluate The Safety And Efficacy Of Two Fixed Doses Of Pf-02545920 Compared To Placebo In The Treatment Of Acute Exacerbation Of Schizophrenia Using Risperidone As An Active Control
In Brief
A Phase 2 clinical trial evaluating PF-02545920, Placebo, and 1 other intervention for Schizophrenia. Completed, enrolled 259 participants across 46 sites in 3 countries.
Detailed Summary
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risperidone and placebo treatment.
Study Details
Timeline
Interventions
5 mg tablet every 12 hours for 28 days
15 mg tablet every 12 hours for 28 days
One tablet/capsule every 12 hours for 28 days
3 mg capsule every 12 hours for 28 days